Association Analysis between g.18873C>T and g.27522G>A Genetic Polymorphisms of OPG and Bone Mineral Density in Chinese Postmenopausal Women

Fei Wang, Yi Cao, Fang Li, Jianlin Shan, and Tianlin Wen

1Department of Orthopaedic Surgery, The General Hospital of Beijing Military Area Command, No. 5 Nannencang Road, Dongcheng District, Beijing 100700, China
2Department of Endocrinology, The General Hospital of Beijing Military Area Command, No. 5 Nannencang Road, Dongcheng District, Beijing 100700, China

Correspondence should be addressed to Fang Li; fangli_12@sina.com

Received 27 May 2014; Accepted 4 August 2014; Published 15 December 2014

Several studies report that the OPG is an important candidate gene in the pathogenesis of osteoporosis. This study aimed to detect the potential association of OPG gene polymorphisms with osteoporosis in postmenopausal women. We recruited 928 subjects containing 463 with primary postmenopausal osteoporosis and 465 healthy volunteers as controls. The BMD of neck hip, lumbar spine (L2–4), and total hip were assessed by dual-energy X-ray absorptiometry (DEXA). Through the created restriction site-polymerase chain reaction (CRS-PCR), PCR-restriction fragment length polymorphism (PCR-RFLP), and DNA sequencing methods, the g.18873C>T and g.27522G>A have been investigated. As for g.18873C>T, our data indicated that subjects with CC genotype have significantly higher BMD value than those of CT and TT genotypes (all \( P \) values < 0.05). As for g.27522G>A, the BMD values of subjects with GG genotype were significantly higher than those of GA and AA genotypes (all \( P \) values < 0.05).

Our findings suggest that the OPG g.18873C>T and g.27522G>A genetic polymorphisms are associated with the decreased risk for osteoporosis in Chinese postmenopausal women.

1. Introduction

Osteoporosis is a multifactorial disease in the postmenopausal women, which is characterized by low bone mineral density (BMD) and deteriorated microarchitecture of bone with the increased susceptibility to fracture [1–9]. BMD is a complex trait that is determined by multiple interaction of environmental, metabolic, and genetic factors [10]. It is well accepted that the genetic factors play key roles in the etiology of osteoporosis [11–16]. Growing evidence indicates that osteoprotegerin gene (OPG) is one of the most important candidate genes for influencing the pathogenesis of osteoporosis [9, 17–26]. Some genetic polymorphisms (such as A163G, T245G, T950C, G1181C, g.18861A>G, and g.27406C>T) in OPG gene have been reported to play genetic influence on BMD and osteoporosis [6, 7, 9, 10, 16, 18, 22, 25–32]. However, there are no similar related studies which reported the relationship of OPG g.18873C>T and g.27522G>A genetic polymorphisms with BMD and osteoporosis. Therefore, this study aims to detect these two OPG genetic polymorphisms and to assess their potential association with BMD and osteoporosis in postmenopausal women.

2. Subjects and Methods

2.1. Studied Subjects. In total, 928 Chinese postmenopausal women were enrolled in this case-control study, containing 463 with primary postmenopausal osteoporosis (aged 45–88 years) and 465 healthy volunteers as controls (aged 47–90 years). All subjects were recruited from the General Hospital of Beijing Military Area Command between January 2009 and November 2013. All individuals were genetically unrelated Chinese Han population and lived in Beijing, China.
Those individuals suffering from present or past history of diseases or taking drugs which could affect bone metabolism were excluded from this study. This study was approved by the Ethics Committee of the General Hospital of Beijing Military Area Command. All participants have provided the informed consent for this study.

2.2. Measurement of BMD.

The BMD of neck hip, lumbar spine ($L_2-4$), and total hip were assessed through dual-energy X-ray absorptiometry (DEXA) (Norland Coopersurgical Corp., WI, USA) [33]. The value of BMD was automatically calculated from bone area ($cm^2$) and bone mineral content (g) and performed as g/cm$^2$.

2.3. DNA Extraction and Genotyping of OPG Genetic Polymorphisms.

The peripheral venous blood was collected from each individual in this case-control study. Genomic DNA were extracted using the DNA isolation kit (Invitrogen, Carlsbad, CA, USA) and stored at −20°C until analyzed. According to the DNA sequences (GenBank ID: NG_012202.1) and mRNA sequences (GenBank ID: NM_002546.3) of the human OPG gene, the specific polymerase chain reaction (PCR) primers were designed by the Primer Premier 5.0 software (Premier Biosoft International, Palo Alto, CA). Table 1 shows the sequences of primers, PCR product regions, annealing temperature, and fragment sizes. The PCR amplifications were performed on a total volume of 20 μL reaction mixture containing 50 ng mixed DNA template, 1x buffer (100 mmol Tris-HCl, pH 8.3; 500 mmol KCl), 0.25 μmol primers, 2.0 mmol MgCl$_2$, 0.25 mmol dNTPs, and 0.5 U Taq DNA polymerase (TaKaRa, Dalian, China). The PCR protocol was carried out in an initial denaturation at 95°C for 5 min, followed by 30 cycles of 94°C for 30 s, annealing at the corresponding temperature (given in Table 1) for 30 s, and 72°C for 30 s, with a final extension at 72°C for 8 min. The genotypes of OPG g.18873C>T genetic polymorphism were investigated by the created restriction site-PCR (CRS-PCR) method with one of the primers containing a nucleotide mismatch, which enables the use of restriction enzymes for discriminating sequence variations [34–38]. Through the PCR-restriction fragment length polymorphism (PCR-RFLP) method, we detected the genotypes of OPG g.27522G>A genetic polymorphism. Following the supplier’s manual, the amplified PCR products (5 μL) were digested with 2 U selected restriction enzymes (performed on Table 1, MBI Fermentas, St. Leon-Rot, Germany) at 37°C for 10 h. The digested PCR products were separated by electrophoresis for 1 h at 100 V on 2.5% agarose gel including 0.5 μg/mL ethidium bromide. The different genotypes were observed directly under ultraviolet (UV) light. To confirm the genotyping test results from CRS-PCR and PCR-RFLP methods, we selected random samples (10% of the total samples) to reanalyze through the DNA sequencing method (ABI3730xl DNA Analyzer, Applied Biosystems, Foster City, CA).

2.4. Statistical Analyses.

The Hardy-Weinberg equilibrium for the genetic variants in the studied subjects was assessed by the chi-squared ($\chi^2$) test. The distribution of allelic and genotypic frequencies was compared in the studied subjects through the chi-squared ($\chi^2$) test. The multiple regression analyses were performed to detect the potential relationships between the variables. All data were shown as the mean ± standard deviation (SD) of the mean. The Statistical Package for Social Sciences software (SPSS, version 17.0; SPSS Inc.; Chicago, IL, USA) was utilized to evaluate all statistical analyses. Statistically significance was set at $P$ value < 0.05.

3. Results

3.1. Identification and Genotyping of OPG Genetic Polymorphisms.

Through the CRS-PCR, PCR-RFLP, and DNA sequencing methods, we have successfully detected and genotyped two OPG genetic polymorphisms (g.18873C>T and g.27522G>A). As for g.18873C>T, our sequence analyses indicate that this genetic polymorphism causes C→T mutation, results into a nonsynonymous mutation in exon 2 at 18873 position of OPG gene, and leads to threonine (Thr) to isoleucine (Ile) amino acid replacement (p.Thr201le, reference sequences GenBank IDs: NG_012202.1, NM_002546.3, and NP_002537.3). The PCR products of g.18873C>T were digested with AciI restriction enzymes and divided into three genotypes, CC (196 bp and 20 bp), CT (216 bp, 196 bp,
and 20 bp), and TT (216 bp, Table 1). As for g.27522G>A, this genetic polymorphism causes G→A mutation. It is a synonymous mutation in exon 5 at 27522 position of OPG gene (p. cysteine (Cys) 319Cys, reference sequences GenBank IDs: NG_012202.1, NM_002546.3, and NP_002537.3). The PCR products of 27522G>A were digested with SphI restriction enzymes and divided into three genotypes, GG (173 bp and 80 bp), GA (253 bp, 173 bp, and 80 bp), and AA (253 bp, Table 1).

### 3.2. Allele and Genotype Frequencies

Table 2 shows the frequencies of allele and genotype for OPG g.18873C>T and g.27522G>A polymorphisms. As for g.18873C>T, the genotypic frequencies in osteoporosis cases (CC, 43.41%; CT, 41.25%; TT, 15.33%) were statistically significantly different from those of healthy controls (CC, 50.97%; CT, 39.78%; TT, 9.25%; \( \chi^2 = 9.9276, P = 0.0070 \)), and significant differences were found between the allele frequencies of cases (C, 66.63%; A, 33.37%) and those of healthy controls (C, 70.86%; T, 29.14%, \( \chi^2 = 11.9014, P = 0.0026 \)). As shown in Table 2, the distributions of these two genetic variants were fitted with Hardy-Weinberg equilibrium (all \( P > 0.05 \)).

### 3.3. OPG Genetic Polymorphisms Associated with BMD

The values of age, weight, height, body mass index (BMI), adjusted neck hip BMD, adjusted spine BMD, and adjusted total hip BMD in the studied subjects are shown in Table 3. Our data indicated that the OPG g.18873C>T and g.27522G>A genetic polymorphisms were statistically associated with the adjusted neck hip BMD, adjusted spine BMD, and adjusted total hip BMD. As for g.18873C>T, subjects with CC genotype had significantly higher adjusted BMD value than those of CT and TT genotypes (all \( P < 0.05 \)). As for g.27522G>A, subjects with GG genotype had significantly higher adjusted BMD value than those of GA and AA genotypes (all \( P < 0.05 \)).

### 4. Discussion

Osteoporosis remains an important and complex health problem in the postmenopausal women in the world. Previous studies indicated that this disease is caused by the combined effects of genetic and environmental factors [16], but the genetic factors play key roles for the development of osteoporosis [11–16]. Evidence from the published reports

| Genotypes | g.18873C>T | g.27522G>A |
|-----------|------------|------------|
| Genotypic frequencies (%) | Allelic frequencies (%) | Genotypic frequencies (%) | Allelic frequencies (%) |
| CC | CT | TT | C | T | \( \chi^2 \) | \( P \) | GG | GA | AA | G | A | \( \chi^2 \) | \( P \) |
| Control (n = 465) | 237 | 185 | 43 | 659 | 271 | 0.6234 | 0.7322 | 226 | 208 | 31 | 660 | 270 | 3.4010 | 0.1826 |
| Total (n = 928) | 438 | 376 | 114 | 1252 | 604 | 5.5256 | 0.0631 | 442 | 393 | 93 | 1277 | 579 | 0.1689 | 0.9190 |

Note: SNPs, single-nucleotide polymorphisms; BMI, body mass index; BMD, bone mineral density; data are shown as mean ± SD (BMD values adjusted by age, weight, and height).

#### Table 2: Genotypic and allelic frequencies of OPG genetic polymorphisms in the studied subjects.

| Groups | Genotypic frequencies (%) | Allelic frequencies (%) | Genotypic frequencies (%) | Allelic frequencies (%) |
|--------|---------------------------|-------------------------|---------------------------|-------------------------|
| Case group (n = 463) | 201 | 191 | 71 | 593 | 333 | 5.0402 | 0.0805 | 216 | 185 | 62 | 617 | 309 | 4.7659 | 0.0923 |
| Control group (n = 465) | 237 | 185 | 43 | 659 | 271 | 0.6234 | 0.7322 | 226 | 208 | 31 | 660 | 270 | 3.4010 | 0.1826 |
| Total (n = 928) | 438 | 376 | 114 | 1252 | 604 | 5.5256 | 0.0631 | 442 | 393 | 93 | 1277 | 579 | 0.1689 | 0.9190 |

\( \chi^2 = 9.9276, P = 0.0070 \) for g.18873C>T and \( \chi^2 = 4.0663, P = 0.0437 \) for g.27522G>A.

#### Table 3: Characteristics of OPG genetic polymorphisms in the total group of subjects.

| SNPs Genotype | g.18873C>T | g.27522G>A |
|---------------|------------|------------|
| Number (%) | 438 (47.20) | 442 (47.63) |
| Age (years) | 62.5 ± 7.8 | 62.9 ± 7.9 |
| Weight (kg) | 61.8 ± 6.6 | 62.8 ± 7.2 |
| Height (cm) | 162 ± 7.7 | 165 ± 6.1 |
| BMI | 23.1 ± 3.76 | 23.3 ± 3.27 |
| Spine BMD (g/cm²) | 0.931 ± 0.111 | 0.830 ± 0.189 |
| Neck hip BMD (g/cm²) | 0.752 ± 0.106 | 0.679 ± 0.134 |
| Total hip BMD (g/cm²) | 0.871 ± 0.123 | 0.809 ± 0.187 |

Note: SNPs, single-nucleotide polymorphisms; BMI, body mass index; BMD, bone mineral density; data are shown as mean ± SD (BMD values adjusted by age, weight, and height).
approved that several OPG genetic polymorphisms have been potentially associated with BMD and osteoporosis [6, 7, 9, 10, 16, 18, 22, 25–32]. However, findings from these observations are still inconsistent, and the exact mechanism of osteoporosis etiology is poorly understood. In this case-control study, we firstly evaluated the genetic effects of OPG g.18873C>T and g.27522G>A genetic polymorphisms on BMD and osteoporosis in Chinese postmenopausal women by association analyses method. Results from this study indicated that there were significant differences in the allelic and genotypic frequencies among primary postmenopausal osteoporosis patients and healthy controls (for g.18873C>T, χ² = 9.9276, P = 0.0070; for g.27522G>A, χ² = 4.0663, P = 0.0437, Table 2). Subjects with the wild genotypes of OPG g.18873C>T and g.27522G>A genetic polymorphisms have the significantly higher value of adjusted neck hip BMD, adjusted spine BMD, and adjusted total hip BMD than those of mutation genotypes (all P values < 0.05, Table 3). The allele-T of g.18873C>T and allele-A of g.27522G>A genetic polymorphisms could contribute to osteoporosis in Chinese postmenopausal women. These preliminary findings provide more evidence that OPG genetic polymorphisms could play genetic effects on BMD and osteoporosis. To the best of our knowledge, this is the first assessment of the influence of OPG g.18873C>T and g.27522G>A genetic polymorphisms with the genetic susceptibility to BMD and osteoporosis. Future replication studies on larger different populations are needed to confirm these findings from this study and to reach more reliable results for assessing the relationship of g.18873C>T and g.27522G>A or other genetic polymorphisms with the etiology of osteoporosis.

Conflict of Interests
The authors have no conflict of interests.

Authors’ Contribution
Fei Wang and Yi Cao have contributed equally to this paper.

References

[1] S. R. Cummings, J. L. Kelsey, M. C. Nevitt, and K. J. O’Dowd, “Epidemiology of osteoporosis and osteoporotic fractures,” Epidemiologic Reviews, vol. 7, pp. 178–208, 1985.
[2] B. L. Riggs and L. J. Melton III, “Involutional osteoporosis,” New England Journal of Medicine, vol. 314, no. 26, pp. 1676–1686, 1986.
[3] J. A. Kanis, L. J. Melton III, C. Christiansen, C. C. Johnston, and N. Khaltaev, “The diagnosis of osteoporosis,” Journal of Bone and Mineral Research, vol. 9, no. 8, pp. 1137–1141, 1994.
[4] L. Geng, Z. Yao, H. Yang, J. Luo, L. Han, and Q. Lu, “Association of CA repeat polymorphism in estrogen receptor beta gene with postmenopausal osteoporosis in Chinese,” Journal of Genetics and Genomics, vol. 34, no. 10, pp. 868–876, 2007.
[5] “Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis,” The American Journal of Medicine, vol. 94, pp. 646–650, 1993.

[6] M. T. Garcia-Unzueta, J. A. Riancho, M. T. Zarrabeitia et al., “Association of the 163A/G and 1181G/C osteoprotegerin polymorphism with bone mineral density,” Hormone and Metabolic Research, vol. 40, no. 3, pp. 219–224, 2008.
[7] Y. H. Lee, J.-H. Woo, S. J. Choi, J. D. Ji, and G. G. Song, “Associations between osteoprotegerin polymorphisms and bone mineral density: a meta-analysis,” Molecular Biology Reports, vol. 37, no. 1, pp. 227–234, 2010.
[8] Y. Li, B. Xi, K. Li, and C. Wang, “Association between vitamin D receptor gene polymorphisms and bone mineral density in Chinese women,” Molecular Biology Reports, vol. 39, no. 5, pp. 5709–5717, 2012.
[9] S. Jurado, X. Nogués, L. Agueda et al., “Polymorphisms and haplotypes across the osteoprotegerin gene associated with bone mineral density and osteoporotic fractures,” Osteoporosis International, vol. 21, no. 2, pp. 287–296, 2010.
[10] H. Ohmori, Y. Makita, M. Funamizu et al., “Linkage and association analyses of the osteoprotegerin gene locus with human osteoporosis,” Journal of Human Genetics, vol. 47, no. 8, pp. 400–406, 2002.
[11] O. M. E. Albagha and S. H. Ralston, “Genetics and Osteoporosis,” Rheumatic Disease Clinics of North America, vol. 32, no. 4, pp. 659–680, 2006.
[12] T. Hosoi, “Genetic aspects of osteoporosis,” Journal of Bone and Mineral Metabolism, vol. 28, no. 6, pp. 601–607, 2010.
[13] S. H. Ralston, “Genetics of osteoporosis,” Annals of the New York Academy of Sciences, vol. 1192, pp. 181–189, 2010.
[14] S. Ferrari, “Human genetics of osteoporosis,” Best Practice & Research Clinical Endocrinology & Metabolism, vol. 22, pp. 723–735, 2008.
[15] C.-L. Cheung, S.-M. Xiao, and A. W. C. Kung, “Genetic epidemiology of age-related osteoporosis and its clinical applications,” Nature Reviews Rheumatology, vol. 6, no. 9, pp. 507–517, 2010.
[16] H.-Y. Zhao, J.-M. Liu, G. Ning et al., “The influence of Lys3Asn polymorphism in the osteoprotegerin gene on bone mineral density in Chinese postmenopausal women,” Osteoporosis International, vol. 16, no. 12, pp. 1519–1524, 2005.
[17] N. A. Pocock, J. A. Eisman, J. L. Hopper, M. G. Yeates, P. N. Sambrook, and S. Eberl, “Genetic determinants of bone mass in adults: a twin study,” The Journal of Clinical Investigation, vol. 80, no. 3, pp. 706–710, 1987.
[18] B. L. Langdahl, M. Carstens, L. Stenkjaer, and E. F. Eriksen, “Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures,” Journal of Bone and Mineral Research, vol. 17, no. 7, pp. 1245–1255, 2002.
[19] B. Arko, J. Preželj, A. Kocijančič, R. Komel, and J. Marc, “Association of the osteoprotegerin gene polymorphisms with bone mineral density in postmenopausal women,” Maturitas, vol. 51, no. 3, pp. 270–279, 2005.
[20] Y. Yamada, F. Ando, N. Niino, and H. Shimokata, “Association of polymorphisms of the osteoprotegerin gene with bone mineral density in Japanese women but not men,” Molecular Genetics and Metabolism, vol. 80, no. 3, pp. 344–349, 2003.
[21] C. Vidal, R. Formosa, and A. Xuereb-Anastasi, “Functional polymorphisms within the TNFRSF11B (osteoprotegerin) gene increase the risk for low bone mineral density,” Journal of Molecular Endocrinology, vol. 47, no. 3, pp. 327–333, 2011.
[22] B. Arko, J. Preželj, R. Komel, A. Kocijančič, P. Hudler, and J. Marc, “Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis,” Journal of Clinical
[23] L. C. Holbauer and M. Schoppet, “Osteoprotegerin gene polymorphism and the risk of osteoporosis and vascular disease,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 9, pp. 4078–4079, 2002.

[24] Y. M. Hussien, A. Shehata, R. A. Karam, S. S. Alzahrani, H. Magdy, and A. M. El-Shafey, “Polymorphism in vitamin D receptor and osteoprotegerin genes in Egyptian rheumatoid arthritis patients with and without osteoporosis,” Molecular Biology Reports, vol. 40, no. 5, pp. 3675–3680, 2013.

[25] L. Paternoster, C. Ohlsson, A. Sayers et al., “OPG and RANK polymorphisms are both associated with cortical bone mineral density: findings from a metaanalysis of the avon longitudinal study of parents and children and Gothenburg osteoporosis and obesity determinants cohorts,” The Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 8, pp. 3940–3948, 2010.

[26] S. P. Moffett, J. I. Oakley, J. A. Cauley et al., “Osteoprotegerin Lys3Asn polymorphism and the risk of fracture in older women,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 5, pp. 2002–2008, 2008.

[27] J. G. Kim, J. H. Kim, J. Y. Kim et al., “Association between osteoprotegerin (OPG), receptor activator of nuclear factor-κB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women,” Menopause, vol. 14, no. 5, pp. 913–918, 2007.

[28] T. Ueland, J. Bollerslev, S. G. Wilson et al., “No associations between OPG gene polymorphisms or serum levels and measures of osteoporosis in elderly Australian women,” Bone, vol. 40, no. 1, pp. 175–181, 2007.

[29] H. L. Jørgensen, P. Kusk, B. Madsen, M. Fenger, and J. B. Lauritzen, “Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios,” Journal of Bone and Mineral Metabolism, vol. 22, no. 2, pp. 132–138, 2004.

[30] L. Shen, Y. Qiu, S. Xing et al., “Association between osteoprotegerin genetic variants and bone mineral density in Chinese women,” International Immunopharmacology, vol. 16, no. 2, pp. 275–278, 2013.

[31] F. Yu, X. Huang, J. Miao, L. Guo, and D. Tao, “Association between osteoprotegerin genetic variants and osteoporosis in Chinese postmenopausal women,” Endocrine Journal, vol. 60, no. 12, pp. 1303–1307, 2013.

[32] Q. Wang, Z. Chen, Y. Huang et al., “The relationship between osteoprotegerin gene polymorphisms and bone mineral density in Chinese postmenopausal women,” International Immunopharmacology, vol. 17, no. 2, pp. 404–407, 2013.

[33] P. Tothill, M. A. Laskey, C. I. Orphanidou, and M. van Wijk, “Anomalies in dual energy X-ray absorptiometry measurements of total-body bone mineral during weight change using Lunar, Hologic and Norland instruments,” British Journal of Radiology, vol. 72, pp. 661–669, 1999.

[34] A. Haliassos, J. C. Chomel, L. Tesson et al., “Modification of enzymatically amplified DNA for the detection of point mutations,” Nucleic Acids Research, vol. 17, no. 9, p. 3606, 1989.

[35] Z. Yuan, J. Li, X. Gao, and S. Xu, “SNPs identification and its correlation analysis with milk somatic cell score in bovine MBL1 gene,” Molecular Biology Reports, vol. 40, no. 1, pp. 7–12, 2013.